Sporos

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis

Houston, TX – May 26, 2022 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that its lead product, TTI-101, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF). The …

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis Read More »

Tvardi Therapeutics

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma

Houston, TX – April 21, 2022 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that its lead product, TTI-101, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC). The FDA …

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma Read More »

Data Demonstrating Tvardi’s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to be Presented at the 2022 Annual Meeting of the American Association for Cancer Research

Houston, TX – April 7, 2022 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced its collaborators will present preclinical data demonstrating TTI-101 overcomes palbociclib resistance in metastatic breast cancer murine models at the upcoming 2022 Annual Meeting of the American Association for Cancer …

Data Demonstrating Tvardi’s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to be Presented at the 2022 Annual Meeting of the American Association for Cancer Research Read More »

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer

Appointment Strengthens Leadership and Expertise to Drive Lead Oncology Program into Phase 1 Clinical Development Founding Chief Executive Officer Dr. Vincent Sandanayaka transitions to role of President and Chief Scientific Officer Boston, Jan. 12, 2022 — Nirogy Therapeutics (“Nirogy” or “the Company”), a privately-held biotechnology company developing novel small molecules to target cellular transporters, today …

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer Read More »

Sporos Bioventures Appoints Dr. Rachel Humphrey to Board of Directors

HOUSTON–(BUSINESS WIRE)– Sporos Bioventures, LLC (“Sporos” or the “Company”), a private biotechnology company catalyzing the rapid development of breakthrough therapies through a portfolio of companies that target novel disease mechanisms in oncology and immune-related diseases, today announced the appointment of Rachel Humphrey, M.D. to its Board of Directors. “We are thrilled to welcome Rachel to …

Sporos Bioventures Appoints Dr. Rachel Humphrey to Board of Directors Read More »

Tvardi Therapeutics

Tvardi Therapeutics Awarded “Most Promising” Company at the 2020 Texas Life Science Forum

Houston, Texas. November 12, 2020 – Tvardi Therapeutics (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, was recognized as one of the 10 Most Promising Life Science Companies at the 2020 Texas Life Science Forum. Hosted by BioHouston and the Rice Alliance, the 2020 Texas Life Science Forum is …

Tvardi Therapeutics Awarded “Most Promising” Company at the 2020 Texas Life Science Forum Read More »

Asylia Therapeutics News

New Company Asylia Therapeutics Finalizes Exclusive Worldwide License Agreement

Asylia Therapeutics (“Asylia”), a new, privately-held, development stage biopharmaceutical company, headquartered in Houston at the Texas Medical Center, has finalized an exclusive worldwide license agreement with The University of Texas MD Anderson Cancer Center to develop first-in-class immune modulating therapies for cancer, autoimmune and infectious diseases, which collectively impact tens of millions of Americans annually. …

New Company Asylia Therapeutics Finalizes Exclusive Worldwide License Agreement Read More »

Tvardi Therapeutics

Tvardi Therapeutics Announces Publication Demonstrating TTI-101 as a Therapeutic Option for Treatment-Resistant Breast Cancers

Tvardi Therapeutics (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced the publication of preclinical studies establishing that its lead compound, TTI-101, is effective against treatment-resistant breast cancers. The paper, published in Clinical Cancer Research, elucidated the STAT3 pathway as the mechanism of resistance and demonstrated that TTI-101 overcame this resistance …

Tvardi Therapeutics Announces Publication Demonstrating TTI-101 as a Therapeutic Option for Treatment-Resistant Breast Cancers Read More »

Tvardi Therapeutics

Tvardi’s TTI-101 Receives $5 Million in Funding to Support Clinical Trials and Translational Research

Houston, TX. July 24, 2020 – Tvardi Therapeutics Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced today its collaborators will receive over $5 million in non-dilutive grants to support the ongoing validation and clinical development of Tvardi’s lead compound, TTI-101. The three National Cancer Institute (NCI) funding …

Tvardi’s TTI-101 Receives $5 Million in Funding to Support Clinical Trials and Translational Research Read More »

Asylia Therapeutics News

Asylia Therapeutics Moves into JLABS @TMC

Houston, Texas. June 6, 2020 – Asylia Therapeutics (“Asylia”), a Texas-based, privately held, development-stage biopharmaceutical company developing novel immune modulating therapies for cancer, autoimmune, and infectious diseases has officially landed at Johnson & Johnson Innovation – JLABS in the Texas Medical Center (JLABS @ TMC). With over 34,000 square feet of common, wet lab, and office …

Asylia Therapeutics Moves into JLABS @TMC Read More »

Scroll to Top